Symbols / ACXP $4.81 +23.97%
ACXP Chart
About
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 12.25M |
| Enterprise Value | 6.18M | Income | -7.97M | Sales | — |
| Book/sh | 2.24 | Cash/sh | 2.65 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -2.19 | PEG | — |
| P/S | — | P/B | 2.14 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 3.14 |
| Current Ratio | 3.18 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.32 | EPS next Y | -2.20 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-13 | ROA | -87.60% |
| ROE | -270.80% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.55M |
| Shs Float | 2.73M | Short Float | 2.28% | Short Ratio | 1.14 |
| Short Interest | — | 52W High | 21.00 | 52W Low | 1.33 |
| Beta | -1.16 | Avg Volume | 2.83M | Volume | 9.54M |
| Target Price | $17.00 | Recom | Strong_buy | Prev Close | $3.88 |
| Price | $4.81 | Change | 23.97% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$17.00
Mean price target
2. Current target
$4.81
Latest analyst target
3. DCF / Fair value
$-47.97
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.81
Low
$10.00
High
$31.00
Mean
$17.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-08-12 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-19 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-12-15 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-08-15 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-04-11 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2022-12-19 | init | HC Wainwright & Co. | — → Buy | $14 |
| 2022-10-20 | init | Alliance Global Partners | — → Buy | $14 |
- Acurx starts recurrent C. diff trial to treat and prevent - Stock Titan Fri, 13 Mar 2026 11
- Acurx Pharmaceuticals Inc expected to post a loss of $1.01 a share - Earnings Preview - TradingView Wed, 11 Mar 2026 12
- Acurx Pharmaceuticals Stock (ACXP) Explodes 218% as New Trial Moves Forward on 96% Cure Rate - TipRanks Fri, 13 Mar 2026 00
- What's Going On With Acurx Pharmaceuticals Stock Today? - Sahm Sat, 14 Mar 2026 21
- Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance ue, 06 Jan 2026 08
- Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough - MEXC Fri, 13 Mar 2026 15
- Acurx Pharmaceuticals (ACXP) Stock Rockets 218% as Phase 3 CDI Trial Gets Green Light - CoinCentral Fri, 13 Mar 2026 12
- Why Is Acurx Pharmaceuticals Stock Up Over 105% Today? - Benzinga Wed, 11 Mar 2026 18
- Market Movers | Winners: ACXP, SAFX, SXTP | Losers: CODX, QNTM, KITT - Trefis hu, 12 Mar 2026 08
- ACXP Acurx Pharmaceuticals NASDAQ 10 Mar 2026: Ibezapolstat trial headlines earnings - Meyka Wed, 11 Mar 2026 00
- Why Is Acurx Pharmaceuticals Stock Falling Thursday? - Sahm Fri, 13 Mar 2026 06
- Acurx Pharmaceuticals (ACXP) Stock Rockets 218% as Phase 3 CDI Trial Gets Green Light - MEXC Fri, 13 Mar 2026 19
- ACXP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan Sat, 07 Mar 2026 18
- Loss-Making Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Expected To Breakeven In The Medium-Term - Yahoo Finance Wed, 21 Jan 2026 08
- 12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga Mon, 16 Mar 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 24631 | 25000 | — | Purchase at price 1.02 per share. | SCODARI JOSEPH C | Director | — | 2025-01-06 00:00:00 | D |
| 1 | 49261 | 50000 | — | Purchase at price 1.02 per share. | DELUCCIA ROBERT J | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-06 00:00:00 | D |
| 2 | 49261 | 50000 | — | Purchase at price 1.02 per share. | LUCI DAVID P | Chief Executive Officer | — | 2025-01-06 00:00:00 | D |
| 3 | 9852 | 10000 | — | Purchase at price 1.02 per share. | DEAN JACK H | Director | — | 2025-01-06 00:00:00 | D |
| 4 | 9852 | 10000 | — | Purchase at price 1.02 per share. | DONOHUE JAMES J. | Director | — | 2025-01-06 00:00:00 | D |
| 5 | 24631 | 25000 | — | Purchase at price 1.02 per share. | SAILER CARL | Director | — | 2025-01-06 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -8.09M | -14.12M | -14.58M | -12.09M |
| TotalUnusualItems | 0.00 | 66.50K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 66.50K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.97M | -14.10M | -14.58M | -12.09M |
| EBITDA | -8.09M | -14.12M | -14.58M | -12.09M |
| EBIT | -8.09M | -14.12M | -14.58M | -12.09M |
| NetInterestIncome | 125.44K | 20.12K | ||
| InterestIncome | 125.44K | 20.12K | ||
| NormalizedIncome | -7.97M | -14.10M | -14.58M | -12.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.97M | -14.10M | -14.58M | -12.09M |
| TotalExpenses | 8.09M | 14.12M | 14.58M | 12.09M |
| DilutedAverageShares | 808.17K | 633.58K | 540.82K | 426.79K |
| BasicAverageShares | 808.17K | 633.58K | 540.82K | 426.79K |
| DilutedEPS | -17.45 | -23.00 | -22.40 | -29.80 |
| BasicEPS | -17.45 | -23.00 | -22.40 | -29.80 |
| DilutedNIAvailtoComStockholders | -7.97M | -14.10M | -14.58M | -12.09M |
| NetIncomeCommonStockholders | -7.97M | -14.10M | -14.58M | -12.09M |
| NetIncome | -7.97M | -14.10M | -14.58M | -12.09M |
| NetIncomeIncludingNoncontrollingInterests | -7.97M | -14.10M | -14.58M | -12.09M |
| NetIncomeContinuousOperations | -7.97M | -14.10M | -14.58M | -12.09M |
| PretaxIncome | -7.97M | -14.10M | -14.58M | -12.09M |
| OtherIncomeExpense | 66.50K | |||
| SpecialIncomeCharges | 0.00 | 66.50K | ||
| OtherSpecialCharges | -66.50K | |||
| NetNonOperatingInterestIncomeExpense | 125.44K | 20.12K | ||
| InterestIncomeNonOperating | 125.44K | 20.12K | ||
| OperatingIncome | -8.09M | -14.12M | -14.58M | -12.09M |
| OperatingExpense | 8.09M | 14.12M | 14.58M | 12.09M |
| ResearchAndDevelopment | 1.83M | 5.40M | 6.04M | 4.75M |
| SellingGeneralAndAdministration | 6.26M | 8.72M | 8.53M | 7.34M |
| GeneralAndAdministrativeExpense | 6.26M | 8.72M | 8.53M | 7.34M |
| OtherGandA | 6.26M | 8.72M | 8.53M | 7.34M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 2.35M | 851.53K | 723.41K | 581.38K |
| ShareIssued | 2.35M | 851.53K | 723.41K | 581.38K |
| TangibleBookValue | 5.27M | 615.12K | 4.67M | 7.32M |
| InvestedCapital | 5.27M | 615.12K | 4.67M | 7.32M |
| WorkingCapital | 5.27M | 615.12K | 4.67M | 7.32M |
| NetTangibleAssets | 5.27M | 615.12K | 4.67M | 7.32M |
| CommonStockEquity | 5.27M | 615.12K | 4.67M | 7.32M |
| TotalCapitalization | 5.27M | 615.12K | 4.67M | 7.32M |
| TotalEquityGrossMinorityInterest | 5.27M | 615.12K | 4.67M | 7.32M |
| StockholdersEquity | 5.27M | 615.12K | 4.67M | 7.32M |
| GainsLossesNotAffectingRetainedEarnings | -38.64M | -26.55M | ||
| OtherEquityAdjustments | -38.64M | -26.55M | ||
| RetainedEarnings | -75.29M | -67.32M | -53.22M | -38.64M |
| AdditionalPaidInCapital | 80.55M | 67.94M | 57.87M | 45.94M |
| CapitalStock | 2.35K | 852.00 | 14.47K | 11.63K |
| CommonStock | 2.35K | 852.00 | 14.47K | 11.63K |
| TotalPartnershipCapital | -53.22M | -38.64M | ||
| TotalLiabilitiesNetMinorityInterest | 2.42M | 3.24M | 3.04M | 2.06M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 2.42M | 3.24M | 3.04M | 2.06M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 39.01K | 537.63K | 716.31K | 542.89K |
| PayablesAndAccruedExpenses | 2.38M | 2.71M | 2.33M | 1.52M |
| CurrentAccruedExpenses | 2.38M | 2.70M | 2.32M | 1.49M |
| Payables | 6.80K | 4.79K | 3.81K | 29.54K |
| OtherPayable | 6.80K | 4.79K | 3.81K | 29.54K |
| TotalAssets | 7.69M | 3.86M | 7.71M | 9.38M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.69M | 3.86M | 7.71M | 9.38M |
| PrepaidAssets | 85.02K | 100.12K | 105.78K | 264.95K |
| Receivables | 48.42K | 51.13K | 129.16K | 0.00 |
| OtherReceivables | 48.42K | 51.13K | 129.16K | |
| CashCashEquivalentsAndShortTermInvestments | 7.56M | 3.71M | 7.47M | 9.11M |
| CashAndCashEquivalents | 7.56M | 3.71M | 7.47M | 9.11M |
| CashFinancial | 7.56M | 3.71M | 7.47M | 9.11M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -6.79M | -10.38M | -9.80M | -7.54M |
| RepurchaseOfCapitalStock | -1.04K | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 6.80M | 6.41M | 5.94M | 3.70M |
| EndCashPosition | 7.56M | 3.71M | 7.47M | 9.11M |
| BeginningCashPosition | 3.71M | 7.47M | 9.11M | 12.96M |
| ChangesInCash | 3.85M | -3.77M | -1.64M | -3.85M |
| FinancingCashFlow | 10.64M | 6.62M | 8.16M | 3.70M |
| CashFlowFromContinuingFinancingActivities | 10.64M | 6.62M | 8.16M | 3.70M |
| ProceedsFromStockOptionExercised | 3.84M | 210.20K | 2.22M | 13.00 |
| NetCommonStockIssuance | 6.80M | 6.41M | 5.94M | 3.70M |
| CommonStockPayments | -1.04K | 0.00 | ||
| CommonStockIssuance | 6.80M | 6.41M | 5.94M | 3.70M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| OperatingCashFlow | -6.79M | -10.38M | -9.80M | -7.54M |
| CashFlowFromContinuingOperatingActivities | -6.79M | -10.38M | -9.80M | -7.54M |
| ChangeInWorkingCapital | -390.96K | 284.09K | 1.01M | 1.25M |
| ChangeInPayablesAndAccruedExpense | -408.78K | 200.40K | 980.75K | 1.22M |
| ChangeInPrepaidAssets | 15.11K | 5.65K | 159.18K | 30.35K |
| ChangeInReceivables | 2.71K | 78.03K | -129.16K | 0.00 |
| OtherNonCashItems | 559.58K | 430.68K | 1.59M | |
| StockBasedCompensation | 1.57M | 3.44M | 3.77M | 3.30M |
| OperatingGainsLosses | 850.26K | |||
| PensionAndEmployeeBenefitExpense | 0.00 | 916.76K | ||
| NetIncomeFromContinuingOperations | -7.97M | -14.10M | -14.58M | -12.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACXP
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|